Ovid Therapeutics Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$7M
R&D
$26M
D&A
$273K
Operating Income
$-42M
EBITDA
$-42M
Interest Income
$2M
Other Income/Expense
$23M
Pretax Income
$-17M
Tax Provision
$0
Net Income
$-17M
Operating Margin
-585.2%
Net Margin
-240.1%
Effective Tax Rate
0.0%
Deferred Tax Liabilities
$48K
DTA Valuation Allowance
$91M
Tax Credit Carryforwards
$2M
NOL Carryforwards
$70M
ETR (Continuing Operations)
-0.5%
ETR Federal Statutory
21.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
0.3%
Operating Lease Cost
$2M
Revenue YoY Variation
1181.3%
Income YoY Variation
31.4%